Avantor Inc. (NYSE:AVTR) stock is trading lower on Friday after the company reported worse-than-expected second-quarter 2025 adjusted EPS.
The company reported adjusted EPS of 24 cents, marginally below the consensus of 25 cents.
AVTR shares are approaching their 52-week low. Track it now here.
The life science tools company reported sales of $1.68 billion, almost in line with the consensus of $1.675 billion.
Sales fell 1% compared to the second quarter of 2024. Foreign currency translation had a positive impact of 2% and M&A had a negative impact of 3%, resulting in flat sales on an organic basis.
Laboratory Solutions sales were $1.12 billion, a reported decrease of 3%. Sales decreased by 1% organically.
Also Read: Goldman Sachs Downgrades Avantor As Shares Spiral 60% Since 2021: ‘We Wrongly Assumed…’
Bioscience Production sales were $561.3 million, a reported decrease of 3%, and a 2% sales increase on an organic basis.
The company said the bioprocessing performance fell short of expectations …